Replies to post #13924 on RespireRx Pharmaceuticals Inc (RSPI)

[zebra4o1]

Madatid,

Amen, a succinct summary of why Psychiatry made this decision. My take is that CX717 or a metabolite gets highly concentrated in some tissue, enough to produce the odd artifact when the tissue dies. This high concentration alone might be enough to make people nervous.

CX717 is still useful as a proof-of-concept compound, but will probably never make it to market. But Cortex has plenty of other compounds in the pipeline which don't produce the artifact. This was a huge setback, and the stock price reflects that. But it's not the end of the Cortex story.

Cortex is definitely a buy at 45 cents. It would be a screaming buy if we weren't in the middle of credit Armageddon. Really wondering what conditions will be like toward the end of 2008 when Cortex will need to raise money.